Abstract: Solitary plasmacytoma and extramedullary plasmocytoma are tumors of malignant character composed of plasma cells, with a mean age of onset at 60 years. They can appear anywhere where the reticuloendothelial system is present. Usually these tumors lead to the development of multiple myeloma in a period of time ranging from 3 to 5 years. We present a rare case handled in our neurosurgery service associated with an unusually long period of evolution.
Introduction
Multiple myeloma (MM) is defined as neoplastic proliferation of plasma cells that make monoclonal protein in most cases. The paraprotein can be found in serum or urine. These lesions extend to extramedullar areas where bone destruction occurs. One of the entities that may arise in the context of MM is plasmacytoma, correlating with a more aggressive course of the disease. Diagnosis is based on clinical symptoms, imaging findings, serum immunoglobulin electrophoresis, and lab studies demonstrating end organ damage (hypercalcemia, anemia, and renal insufficiency). Diagnosis is confirmed by histopathologic analysis following tissue biopsy or bone marrow aspirate. We present the case of a patient with a giant frontal lesion, which was consistent with a plasmacytoma associated with long period of evolution.
Case report
Male patient, 47-yo, from rural area, with history of been working in palm oil production, fishing and construction for several years. Is admitted to our institution referred from a first level care center, because of the presence of a large frontal lesion associated with head trauma 30 years ago, which was gradually increasing in size. The patient referred dyspnea on moderate exercise and fatigue. On examination, the patient was in regular conditional, afebrile, hydrated, hemodynamically compensated, normal vital signs, a lesion protrude in the medial frontal region, 15 x 15 cms (Figures 1A and B) soft at touch; no lymphadenopathy, cardiopulmonary, abdomen and extremities were normal. It was decided to perform skull radiography, head CT-scan (Figures 2, 3A, 3B ).
Images were evaluated, and we decided to perform frontal craniotomy with tumor resection. Patient developed mediate and immediate satisfactory postoperative course. During ICU stance the patient status declines, developing hyperazoemia. The pathology report was consistent with a lesion composed of plasma cells. The nephrology service establishes the diagnosis of renal failure; the patient progressed without improvement and died from respiratory complications. The diagnosis of SPB or EP is made by the presence of a single plasmacytoma in the bone or the soft tissue and the absence of clinical, histologic, and radiological evidence of multiple myeloma; (4) they have a mean age of presentation of about 10 years younger than those who develop MM. (4) Most patients with plasma cell neoplasms present initially with vague symptoms, such as bone pain, anemia, or fatigue. The first rational approach for differential diagnosis of the SPB or EP is the exclusion of other plasma cell dyscrasias and, particularly dissemination of the disease into MM. This evaluation requires complete blood count with white cell differential, erythrocyte sedimentation rate, serum calcium, phosphorous, blood urea nitrogen, creatinine, serum and urine protein electrophoresis, bone marrow biopsy, chest radiograph, and a radiographic skeletal survey. (5) Skeletal survey may detect lytic lesions, compression fractures (pathological), and osteopenia in areas with hemopoietically active bone marrow (vertebrae, ribs, femur, humerus, pelvis, sternum, and skull). (4-6) Bone marrow biopsy is required to detect malignant, plasmacytosis >10% is suggestive of MM.6 Regard the serum protein electrophoresis, it shows a sharp spike called the M component (M for monoclonal). When present, elevation of creatinine and uric acid is indicative of impaired renal function due to blockage of renal tubules by paraproteins and increased tumor load. The systemic search must persist for at least a year after the discovery of an intracranial plasmacytoma, especially if the mass is located in the skull base. (7) Treatment Some difficulties limit the correct approach of treatment for these patients, especially for the small number of patients and the lack of controlled trials with statistically significant results, making that treatment of choice stills doubtful. Radiotherapy is the most accepted therapeutic strategy; other treatment choices are surgery, the combination of radiotherapy and surgery, and chemotherapy. (11) reported the similar case of SPB in skull. CT scan revealed an 8 cm × 9 cm osteolytic lesion on the scalp of skull with a well demarcated margin. A cakelike mass was revealed at CT soft tissue window. The mass was completely excised.
The level of response to treatment, and in particular, the complete response, is associated with better long-term results. These patients should be followed every three months to assess the appearance of new signs or symptoms of disease; and note that survival solitary plasmacytoma is longer than multiple myeloma patients in the absence of diffuse abnormalities in the bone marrow, kidney lesions and calcium metabolism.
The main prognostic indicator for SPB and EP is the progression to MM, being the cranial base location the strongest predictor for that progression. 
Conclusions
Plasmatic cell tumors are a rare disease, representing less than 1% of tumors of the head and neck. Usually they come from the brain parenchyma, or from dural or bone infiltration. Sometimes this type of injury is associated with MM. This last fact is the rationale for differential diagnosis of the SPB or EP is the exclusion of other plasma cell dyscrasias. Unlike MM, SPB and EP are localized disease of plasma cells without commitment systemic complications such as renal failure, hematological disorders, neurological and immunological. Pain and bone destruction with pathological fractures represent the most common clinical signs of this disease; therefore sometimes lab results are similar to MM as calcium disorders, renal dysfunction and increased beta-2 microglobulin; plasmacytoma therefore has a better prognosis than MM.
